Advertisement

Topics

Latest "Global Initiative Alzheimer Disease Optum Labs" News Stories - Page: 4

21:25 EDT 20th October 2018 | BioPortfolio

Here are the most relevant search results for "Global Initiative Alzheimer Disease Optum Labs" found in our extensive news archives from over 250 global news sources.

More Information about Global Initiative Alzheimer Disease Optum Labs on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Global Initiative Alzheimer Disease Optum Labs for you to read. Along with our medical data and news we also list Global Initiative Alzheimer Disease Optum Labs Clinical Trials, which are updated daily. BioPortfolio also has a large database of Global Initiative Alzheimer Disease Optum Labs Companies for you to search.

Showing "Global Initiative Alzheimer Disease Optum Labs" News Articles 76–100 of 30,000+

Relevant

MediPharm Labs Corp. (TSXV:LABS) Commences Trading on the TSXV

MediPharm Labs Inc. (TSXV: LABS) (“MediPharm Labs” or the “Company”) (formerly POCML 4 Inc.; TSXV: POCM) is pleased to provide a corporate update to highlight its achievements and ongoing activities upon the commencement of trading of its common shares on the TSX Venture Exchange (the “TSXV”) on October 4, 2018 under the ticker symbol “LABS”. The post MediPharm Labs Corp. (TSXV:LA...


EU countries unprepared to move future Alzheimer's treatment into rapid clinical use

(RAND Corporation) The burden of Alzheimer's disease in high-income countries is expected to nearly double by 2050 and recent positive results from clinical trials give hope that a disease-changing treatment could become available for routine use within a few years. But a new study finds that the health care systems in some European countries lack the capacity to rapidly move a disease-modifying t...

Study: Alzheimer's drug may stop disease if used before symptoms develop

(University of Virginia) Biologists have gained new understanding of how Alzheimer's disease begins, and how it might be halted using a current medication.


We Can Control One Of The Likely Causes Of Alzheimer's Disease

Over 5.5M people in the U.S. have Alzheimer's disease with an increase expected. We don't know the causes but research has shown it to be likely that heavy metal exposure is one of them. We can reduce our risk and that of our aging parents in several ways.

Herpes virus linked to Alzheimer’s, antivirals may help – Independent Online

Independent OnlineHerpes virus linked to Alzheimer's, antivirals may helpIndependent OnlineLondon - Scientists have found evidence of a link between herpes infection and Alzheimer's disease as well as the potential of antivirals in reducing the risk of the neurodegenerative disease. In the study, when people who suffered with severe herpes ...Alzheimer's risk 10 times lower with herpes medicationM...

AstraZeneca, Eli Lilly terminate clinical trials of Alzheimer's disease treatment lanabecestat

AstraZeneca and Eli Lilly have announced the termination of global phase 3 clinical trials of Alzheimer's disease treatment, lanabecestat, which is an oral beta secretase cleaving enzyme (BACE) inhibitor.

Lifetime Risks Temper Biomarker Tests for Alzheimer Dz Dementia

WEDNESDAY, June 6, 2018 -- The lifetime risks of Alzheimer's disease (AD) dementia vary considerably by age, gender, and the preclinical or clinical disease state, according to a study published online May 22 in Alzheimer's & Dementia. Ron...

Gut Microbiota Signature Altered in Alzheimer's Disease

The composition of gut microbiota is altered in patients with Alzheimer's disease, potentially supporting the inflammatory theory of the disease's pathogenesis, new research suggests. Medscape Medical News

Discovery and validation of autosomal dominant Alzheimer’s disease mutations

Alzheimer’s disease (AD) is a neurodegenerative disease that is clinically characterized by progressive cognitive decline. Mutations in amyloid-β precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (P...

[Articles] Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study

Plasma NfL and CSF biomarkers have good diagnostic performance to detect Alzheimer's disease in adults with Down syndrome. Our findings support the utility of plasma NfL for the early detection of Alzheimer's disease in Down syndrome in clinical practice and clinical trials.

Senolytic Therapies Seem To Stop Alzheimer's Disease "In Its Tracks"

Scientists have implicated a type of cellular stress for the first time as a player in Alzheimer's disease. And their discovery could lead to treatments for more than 20 human brain diseases.

Senolytic Therapies Seem To Stop Alzheimer's Disease 'In Its Tracks'

Scientists have implicated a type of cellular stress for the first time as a player in Alzheimer's disease. And their discovery could lead to treatments for more than 20 human brain diseases.

European countries unprepared for Alzheimer's innovations, study shows

European healthcare systems are not prepared for new developments in preventative therapies for Alzheimer’s disease, according to research conducted by the American non-profit think tank, the RAND Corporation. While it is believed that Alzheimer’s disease is not curable, current hypotheses pose that the neurodegenerative condition may be prevented. There are currently therapies in development ...

PET imaging of tau may help distinguish Alzheimer Disease from other neurodegenerative disorders

1. In this cross-sectional study, the tau marker [18F]flortaucipir accurately distinguished Alzheimer’s Disease (AD) dementia from other non-AD neurodegenerative disorders about 90% of the time. 2. [18F]flortaucipir imaging more accurately identified AD compared to MRI-based measures of brain atrophy specific associated with AD. Evidence Rating Level: 2 (Good) Study Rundown: Alzheimer’s Diseas...

Report: Alzheimer’s market offers scope for disease-modifying drugs

The current competitive market for Alzheimer’s disease focuses only on symptomatic treatments, providing an opening for urgent new disease-modifying drugs...Read More... The post Report: Alzheimer’s market offers scope for disease-modifying drugs appeared first on Pharmaceutical Technology.

Exosomes Shown to be Involved in Spread of Amyloid Beta in Alzheimer’s

Researchers report that exosomes appear to play a key role in the spread of Alzheimer's disease in the brain. Long understood that the main task of exosomes was to help the cell get rid of waste products, it’s now known that exosomes can contain both proteins and genetic material, which other cells can absorb, explain the scientists. In a new study (“ Alzheimer’s disease pathology pr...

Detecting Alzheimer's disease before it's too late

The rate at which the protein beta-amyloid accumulates into the sticky plaques associated with Alzheimer's disease (AD) is already slowing by the time a patient would be considered to have preclinical AD, according to a longitudinal study of healthy adults.

Research reveals how Tau aggregates can contribute to cell death in Alzheimer's disease

(Baylor College of Medicine) New evidence suggests a mechanism by which progressive accumulation of Tau protein in brain cells may lead to Alzheimer's disease.

Podcast: The problematic promise of a ‘cure’ for Alzheimer’s disease

The Alzheimer's Association has fundraising commercials promising breakthroughs and cures for a disease in which the cause is unknown and a treatment hasn't been found. Is this irresponsible? Unethical? Potentially harmful?

Promising DMT candidate for Alzheimer’s disease could reach trials in 2019

A new therapeutic antibody candidate for the treatment of Alzheimer’s disease (AD), PMN310, showed promising results according to its developer,...Read More... The post Promising DMT candidate for Alzheimer’s disease could reach trials in 2019 appeared first on Pharmaceutical Technology.

A new era in Alzheimer’s innovation

After heart disease and cancer, Alzheimer’s disease and dementia are the leading cause of death for seniors, responsible for one out of every three deaths. Today, the disease devastates the minds of people of all ages and creates substantial burdens for families and caregivers. By 2060, the number of patients affected is expected to double from

Lilly and AstraZeneca Discontinue Late-Stage Trials of Lanabecestat for the Treatment of Alzheimer’s Disease

INDIANAPOLIS, June 12, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and AstraZeneca are discontinuing the global Phase 3 clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer’s disease. The decision is based on recommendations by an independent data monitoring committee (IDMC) which concluded that both …

NIH-funded study finds new evidence that viruses may play a role in Alzheimer’s disease

(NIH/National Institute on Aging) Analysis of large data sets from post-mortem brain samples of people with and without Alzheimer's disease has revealed new evidence linking viruses to Alzheimer's clinical traits and genetic factors. Researchers funded by the National Institute on Aging (NIA), part of the National Institutes of Health, made the discovery by harnessing data from brain banks and coh...

Pharmacogenetics of angiotensin-converting enzyme inhibitors for Alzheimer's disease

(Bentham Science Publishers) The researchers aimed to investigate whether ACE gene polymorphisms rs1800764 and rs4291 are associated with cognitive and functional change in patients with Alzheimer's disease.

New research reveals a mitochondrial gene that protects against Alzheimer's disease

A previously unknown genetic risk factor for Alzheimer's disease and related dementias has been uncovered in a new study, which provides insights on how diseases of aging might one day be treated and prevented.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks